Rimegepant + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Trigeminal Neuralgia
Conditions
Trigeminal Neuralgia
Trial Timeline
Jun 25, 2019 → May 11, 2023
NCT ID
NCT03941834About Rimegepant + Placebo
Rimegepant + Placebo is a phase 2 stage product being developed by Pfizer for Trigeminal Neuralgia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03941834. Target conditions include Trigeminal Neuralgia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06616194 | Phase 3 | Recruiting |
| NCT05810038 | Phase 3 | Completed |
| NCT05518123 | Approved | Completed |
| NCT05399485 | Phase 3 | Completed |
| NCT05262517 | Phase 3 | Terminated |
| NCT05156398 | Phase 3 | Recruiting |
| NCT04629950 | Phase 2 | Completed |
| NCT04574362 | Phase 3 | Completed |
| NCT03941834 | Phase 2 | Terminated |
| NCT03732638 | Phase 2/3 | Completed |
| NCT03461757 | Phase 3 | Completed |
| NCT03237845 | Phase 3 | Completed |
| NCT03235479 | Phase 3 | Completed |
Competing Products
7 competing products in Trigeminal Neuralgia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab | Eli Lilly | Approved | 85 |
| Erenumab-Aooe | Amgen | Phase 2 | 51 |
| BIIB074 Treatment A + BIIB074 Treatment B + BIIB074 Treatment C + BIIB074 Treatment D | Biogen | Phase 1 | 30 |
| CNV1014802 + Placebo | Biogen | Phase 1 | 30 |
| CNV1014802 + Placebo | Biogen | Phase 2 | 49 |
| BIIB074 + Placebo | Biogen | Phase 3 | 74 |
| BIIB074 + Placebo | Biogen | Phase 3 | 74 |